Search
Displaying 91–100 of 1178 results
-
In the Press
Four-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
Foundation News
The gathering will be held June 12–13 and will convene global communities impacted by blinding diseases, alongside researchers, clinicians, patient advocates, and industry partners to foster collaboration, innovation, and hope.
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
The Foundation Fighting Blindness, together with the Nixon Visions Foundation, invites you to join a free, in-person workshop bringing together individuals and families affected by PRPH2 and associated retinal diseases, along with researchers, physicians, and industry partners.
-
Mental Health: Why AI Therapists Can’t Replace Human Connection
WellnessOn their own, digital apps fall short for one reason: the primary catalyst for personal growth and happiness is connection. Not just to a screen or to the words someone is typing, but to a living, breathing person who can empower you to change at the deepest level.
-
Seen at Last: How Love Is Blind Gave Madison a Platform for RP
Beacon StoriesFrom reality TV to real-world impact, Madison Maidenberg turned her Love Is Blind spotlight into a platform for blinding diseases. As a contestant living with retinitis pigmentosa, she’s challenging misconceptions about blindness and becoming a powerful voice for the blind and low vision community.
-
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
Research NewsStrategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
-
Recording Available: Insights Forum | Thursday, March 26, 2026
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on March 26, 2026.
